Publication | Closed Access

Improvement of metabolic disorders and visceral fat obesity by the β3-adrenoceptor agonist (R∗,R∗)-(±)-methyl-4-[2-[2-hydroxy-2-(3-chlorophenyl)ethylamino]propyl]-phenoxyacetate hydrobromide (BRL35135A) in genetically obese rodents

ObesityMetabolic SyndromeCaloric RestrictionEnergy HomeostasisVisceral Fat ObesityBiochemistryβ3-Adrenoceptor AgonistMedicineMetabolic DisorderPhysiologyMetabolic SignalingEndocrinologyObese RodentsMetabolismPharmacologyHuman MetabolismMetabolic HealthHealth Sciences